Predictors of fluoxetine remission for hospitalized patients with major depressive disorder

Psychiatry and Clinical Neurosciences

Volumn 65, Issue 5, 2011, Pages 510-517

  Lin, Ching Hua ^a,b   Lane, Hsien Yuan ^e,f   Chen, Cheng Chung ^a   Juo, Suh Hang Hank ^b,c,d   Yen, Cheng Fang ^b,c  

^a Kai Suan Psychiatric Hospital   (Taiwan)

^b School of Chinese Medicine   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

fluoxetine; major depressive disorder; pain; remission

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE;

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HAMILTON SCALE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL DISEASE; OPEN STUDY; PATIENT COMPLIANCE; PREDICTION; PSYCHOPHARMACOTHERAPY; REMISSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSIVE DISORDER, MAJOR; FEMALE; FLUOXETINE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PAIN; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION;

EID: 80051995449     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2011.02235.x     Document Type: Article

References (63)

1. Thase ME,. Evaluating antidepressant therapies: remission as the optimal outcome. J. Clin. Psychiatry 2003; 64 (Suppl. 13): 18-25. (Pubitemid 37267811)
2. Stahl SM,. Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy. J. Clin. Psychiatry 1999; 60: 213-214. (Pubitemid 29193916)
3. Nierenberg AA, Wright EC,. Evolution of remission as the new standard in the treatment of depression. J. Clin. Psychiatry 1999; 60 (Suppl. 22): 7-11. (Pubitemid 30107949)
4. Rush AJ, Crismon ML, Toprac MG, et al,. Consensus guidelines in the treatment of major depressive disorder. J. Clin. Psychiatry 1998; 59 (Suppl. 20): 73-84. (Pubitemid 29001831)
5. Mintz J, Mintz LI, Arruda MJ, Hwang SS,. Treatments of depression and the functional capacity to work. Arch. Gen. Psychiatry 1992; 49: 761-768.
6. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am. J. Psychiatry 2000; 157: 1-45.
7. Patten SB, Kennedy SH, Lam RW, et al,. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. J. Affect. Disord. 2009; 117 (Suppl. 1): S5-14.
8. Judd LL, Paulus MJ, Schettler PJ, et al,. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am. J. Psychiatry 2000; 157: 1501-1504.
9. Judd LL, Akiskal HS, Maser JD, et al,. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J. Affect. Disord. 1998; 50: 97-108. (Pubitemid 28551779)
10. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A,. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 1995; 25: 1171-1180.
11. Hamilton M,. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960; 23: 56-62.
12. Fava M,. Diagnosis and definition of treatment-resistant depression. Biol. Psychiatry 2003; 53: 649-659. (Pubitemid 39658481)
13. Trivedi MH, Rush AJ, Wisniewski SR, et al,. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 2006; 163: 28-40. (Pubitemid 43050100)
14. Thase ME, Entsuah AR, Rudolph RL,. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001; 178: 234-241. (Pubitemid 32183606)
15. Leuchter AF, Cook IA, Gilmer WS, et al,. Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res. 2009; 169: 132-138.
16. Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Sokero TP, Isometsa ET,. Severity and comorbidity predict episode duration and recurrence of DSM-IV major depressive disorder. J. Clin. Psychiatry 2004; 65: 810-819.
17. Rush AJ, Giles DE, Jarrett RB, et al,. Reduced REM latency predicts response to tricyclic medication in depressed outpatients. Biol. Psychiatry 1989; 26: 61-72. (Pubitemid 19139944)
18. Kugaya A, Sanacora G, Staley JK, et al,. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biol. Psychiatry 2004; 56: 497-502. (Pubitemid 39278247)
19. Ueda N, Yoshimura R, Shinkai K, Nakamura J,. Plasma levels of catecholamine metabolites predict the response to sulpiride or fluvoxamine in major depression. Pharmacopsychiatry 2002; 35: 175-181.
20. Szegedi A, Muller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O,. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J. Clin. Psychiatry 2003; 64: 413-420. (Pubitemid 36547285)
21. Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME,. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J. Clin. Psychiatry 2009; 70: 344-353.
22. Katon W, Sullivan M, Walker E,. Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann. Intern. Med. 2001; 134: 917-925. (Pubitemid 32405701)
23. Kroenke K,. Studying symptoms: sampling and measurement issues. Ann. Intern. Med. 2001; 134: 844-853. (Pubitemid 32405692)
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC, 1994.
25. Gallagher RM, Verma S,. Managing pain and comorbid depression: a public health challenge. Semin. Clin. Neuropsychiatry 1999; 4: 203-220.
26. Blier P, Abbott FV,. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. J. Psychiatry Neurosci. 2001; 26: 37-43. (Pubitemid 32185178)
27. Basbaum AI, Fields HL,. Endogenous pain control mechanisms: review and hypothesis. Ann. Neurol. 1978; 4: 451-462. (Pubitemid 9030389)
28. Corruble E, Guelfi JD,. Pain complaints in depressed inpatients. Psychopathology 2000; 33: 307-309.
29. Bair MJ, Robinson RL, Katon W, Kroenke K,. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 2003; 163: 2433-2445. (Pubitemid 37385786)
30. Karp JF, Scott J, Houck P, Reynolds CF 3rd, Kupfer DJ, Frank E,. Pain predicts longer time to remission during treatment of recurrent depression. J. Clin. Psychiatry 2005; 66: 591-597. (Pubitemid 40733701)
31. Ang QQ, Wing YK, He Y, et al,. Association between painful physical symptoms and clinical outcomes in East Asian patients with major depressive disorder: a 3-month prospective observational study. Int. J. Clin. Pract. 2009; 63: 1041-1049.
32. Bair MJ, Robinson RL, Eckert GJ, Stang PE, Croghan TW, Kroenke K,. Impact of pain on depression treatment response in primary care. Psychosom. Med. 2004; 66: 17-22. (Pubitemid 38146528)
33. Kroenke K, Shen J, Oxman TE, Williams JW Jr, Dietrich AJ,. Impact of pain on the outcomes of depression treatment: results from the RESPECT trial. Pain 2008; 134: 209-215. (Pubitemid 350251018)
34. Leuchter AF, Husain MM, Cook IA, et al,. Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. Psychol. Med. 2010; 40: 239-251.
35. Mavandadi S, Ten Have TR, Katz IR, et al,. Effect of depression treatment on depressive symptoms in older adulthood: the moderating role of pain. J. Am. Geriatr. Soc. 2007; 55: 202-211. (Pubitemid 46184395)
36. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM,. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J. Clin. Psychiatry 2004; 65: 521-530.
37. American Psychiatric Association. Structured Clinical Interview for DSM-IV. American Psychiatric Press, Washington, DC, 1994.
38. Guy W,. ECDEU Assessment Manual for Psychopharmacology. DHEW Publication 76338, Washington, DC, 1976.
39. Stokes PE,. Fluoxetine: a five-year review. Clin. Ther. 1993; 15: 216-243. discussion 215. (Pubitemid 23168487)
40. Fava M, Rush AJ, Alpert JE, et al,. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am. J. Psychiatry 2008; 165: 342-351. (Pubitemid 351704490)
41. Thielke SM, Fan MY, Sullivan M, Unutzer J,. Pain limits the effectiveness of collaborative care for depression. Am. J. Geriatr. Psychiatry 2007; 15: 699-707.
42. Means-Christensen AJ, Roy-Byrne PP, Sherbourne CD, Craske MG, Stein MB,. Relationships among pain, anxiety, and depression in primary care. Depress. Anxiet 2008; 25: 593-600.
43. Teh CF, Morone NE, Karp JF, et al,. Pain interference impacts response to treatment for anxiety disorders. Depress. Anxiet 2009; 26: 222-228.
44. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K,. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 1987; 334: 1-100. (Pubitemid 17115352)
45. Frank E, Prien RF, Jarrett RB, et al,. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch. Gen. Psychiatry 1991; 48: 851-855.
46. Von Korff M, Simon G,. The relationship between pain and depression. Br. J. Psychiatry Suppl. 1996; 30: 101-108. (Pubitemid 26179810)
47. Tedlow J, Fava M, Uebelacker L, Nierenberg AA, Alpert JE, Rosenbaum J,. Outcome definitions and predictors in depression. Psychother. Psychosom. 1998; 67: 266-270. (Pubitemid 28386472)
48. Souery D, Oswald P, Massat I, et al,. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J. Clin. Psychiatry 2007; 68: 1062-1070. (Pubitemid 47340327)
49. Paykel ES,. The clinical interview for depression. Development, reliability and validity. J. Affect. Disord. 1985; 9: 85-96. (Pubitemid 15068952)
50. Rush AJ, Trivedi MH, Wisniewski SR, et al,. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006; 163: 1905-1917. (Pubitemid 44807782)
51. Keitner GI, Ryan CE, Miller IW, Norman WH,. Recovery and major depression: factors associated with twelve-month outcome. Am. J. Psychiatry 1992; 149: 93-99.
52. Nakajima S, Suzuki T, Watanabe K, Kashima H, Uchida H,. Accelerating response to antidepressant treatment in depression: a review and clinical suggestions. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010; 34: 259-264.
53. Uher R, Farmer A, Henigsberg N, et al,. Adverse reactions to antidepressants. Br. J. Psychiatry 2009; 195: 202-210.
54. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C,. What constitutes an adequate antidepressant trial for fluoxetine? J. Clin. Psychiatry 1990; 51: 8-11. (Pubitemid 20042560)
55. Beasley CM Jr, Nilsson ME, Koke SC, Gonzales JS,. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. J. Clin. Psychiatry 2000; 61: 722-728.
56. Gram L,. Fluoxetine. N. Engl. J. Med. 1994; 331: 1354-1361. (Pubitemid 24984727)
57. Khan A, Leventhal RM, Khan SR, Brown WA,. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J. Clin. Psychopharmacol. 2002; 22: 40-45. (Pubitemid 34101291)
58. Nierenberg AA, Farabaugh AH, Alpert JE, et al,. Timing of onset of antidepressant response with fluoxetine treatment. Am. J. Psychiatry 2000; 157: 1423-1428.
59. Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z,. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch. Gen. Psychiatry 2006; 63: 1217-1223. (Pubitemid 44708080)
60. Stassen HH, Angst J, Hell D, Scharfetter C, Szegedi A,. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J. Clin. Psychiatry 2007; 68: 1195-1205. (Pubitemid 47395621)
61. Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M,. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am. J. Psychiatry 1995; 152: 1500-1503.
62. Ohayon MM,. Specific characteristics of the pain/depression association in the general population. J. Clin. Psychiatry 2004; 65 (Suppl. 12): 5-9.
63. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM,. Prevalence of chronic benign pain disorder among adults: a review of the literature. Pain 1998; 77: 231-239. (Pubitemid 28451511)